Assess whether scientific advice should be sought before the next trial

SITUATION After a boxed-warning proposal from the review division, disproportionate reporting signal workbook is what pharmacovigilance medical reviewer can touch in a rare-disease team designing a pediatric plan. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Clinical and Evidence Strategy file.

DECISION Pharmacovigilance medical reviewer in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; disproportionate reporting signal workbook already has the discriminator after a boxed-warning proposal from the review division. 2. Keep Pause the pathway in force until disproportionate reporting signal workbook is completed after a boxed-warning proposal from the review division for pharmacovigilance medical reviewer. 3. Treat disproportionate reporting signal workbook as Escalate safety review because both readings appear after a boxed-warning proposal from the review division. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision scientific advice should be turns on in disproportionate reporting signal workbook.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a rare-disease team designing a pediatric plan. 2. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move scientific advice should be for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). If disproportionate reporting signal workbook cannot force a Pharma & Life Sciences label under Clinical and Evidence Strategy, stop. If disproportionate reporting signal workbook after a boxed-warning proposal from the review division cannot support Proceed under protocol versus Pause the pathway on this Pharma & Life Sciences Clinical and Evidence Strategy close, pharmacovigilance medical reviewer must state the unresolved clinical or safety evidence requirement explicitly.